These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21179868)

  • 21. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Wood L; Campbell RK
    Pharmacotherapy; 2010 May; 30(5):463-84. PubMed ID: 20411998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin detemir: a new basal insulin analogue.
    Soran H; Younis N
    Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin glargine for type 2 diabetes.
    Hemraj F; Garces K
    Issues Emerg Health Technol; 2004 Aug; (59):1-4. PubMed ID: 15311441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y; Guo XH; Vaz JA;
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Indications for a favourable effect of intensive insulin therapy for newly-diagnosed type 2 diabetes].
    Roep BO; Pijl H
    Ned Tijdschr Geneeskd; 2008 Nov; 152(44):2378-80. PubMed ID: 19055134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incretins: cardiovascular safety and rationale for use.
    Kok A
    Cardiovasc J Afr; 2013 Mar; 24(2):46. PubMed ID: 23750348
    [No Abstract]   [Full Text] [Related]  

  • 28. [Type 2 diabetes. A new kind of insulin sensitizer at the door].
    Böhm S
    MMW Fortschr Med; 1999 Jul; 141(27):56-7. PubMed ID: 10904588
    [No Abstract]   [Full Text] [Related]  

  • 29. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
    Lloyd DJ; Helmering J; Cordover D; Bowsman M; Chen M; Hale C; Fordstrom P; Zhou M; Wang M; Kaufman SA; Véniant MM
    Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensive insulin therapy in newly diagnosed type 2 diabetes.
    Retnakaran R; Drucker DJ
    Lancet; 2008 May; 371(9626):1725-6. PubMed ID: 18502278
    [No Abstract]   [Full Text] [Related]  

  • 31. Tapping incretin-based therapy for type 2 diabetes.
    Appel SJ
    Nursing; 2011 Mar; 41(3):49-51. PubMed ID: 21326056
    [No Abstract]   [Full Text] [Related]  

  • 32. What to do after basal insulin: 3 Tx strategies for type 2 diabetes.
    Presswala L; Shubrook J
    J Fam Pract; 2015 Apr; 64(4):214-20. PubMed ID: 25973447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tenacious D. why beta cells are no match for the relentless persistence of type 2 diabetes.
    Curry A
    Diabetes Forecast; 2015; 68(5):38-41. PubMed ID: 26491753
    [No Abstract]   [Full Text] [Related]  

  • 34. [Diabetes in 2015: constantly increasing, but with enlarged therapeutics options].
    Jornayvaz FR; Philippe J
    Rev Med Suisse; 2015 Jun; 11(477):1219-20. PubMed ID: 26211280
    [No Abstract]   [Full Text] [Related]  

  • 35. Investigational agents that protect pancreatic islet beta-cells from failure.
    Aston-Mourney K; Proietto J; Andrikopoulos S
    Expert Opin Investig Drugs; 2005 Oct; 14(10):1241-50. PubMed ID: 16185166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In support of an early intensive treatment of type 2 diabetes and not necessarily of early polypharmacy.
    Czupryniak L; Szymańska-Garbacz E; Pawłowski M; Saryusz-Wolska M; Loba J
    Diabetes Obes Metab; 2011 May; 13(5):474-5. PubMed ID: 22017762
    [No Abstract]   [Full Text] [Related]  

  • 37. Hypoglycemic agents in the management of type 2 diabetes mellitus.
    Ho J; Leung AK; Rabi D
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Jan; 5(1):66-73. PubMed ID: 22074580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SGLT inhibition in patients with type 1 diabetes.
    Dehn CA
    Lancet Diabetes Endocrinol; 2014 Jul; 2(7):539. PubMed ID: 24920585
    [No Abstract]   [Full Text] [Related]  

  • 39. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
    Majumdar SK; Inzucchi SE
    Endocrine; 2013 Aug; 44(1):47-58. PubMed ID: 23354728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. American Diabetes Association--69th Scientific sessions. Obesity management and treatment of type 2 diabetes: Part 1.
    Kouremenou C
    IDrugs; 2009 Aug; 12(8):463-4. PubMed ID: 19629873
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.